GA
CLDX icon

Geneva Advisors’s Celldex Therapeutics CLDX Stock Holding History

Geneva Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-749
Closed -$283K – 653
2015
Q2 		$283K Buy
749
+237
+46% +$94.1K 0.01% 535
2015
Q1 		$214K Buy
+512
New +$183K ﹤0.01% 583

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Geneva Advisors's CLDX Position: Q3 2015 in Review

Geneva Advisors sold out of Celldex Therapeutics (CLDX) in Q3 2015, closing a stake of 749 shares — an estimated $283K sold.

Geneva Advisors first reported a position in CLDX in Q1 2015 and held it in 2 quarters. The position peaked at $283K in Q2 2015. 162 funds tracked by Wall St. Rank hold CLDX as of Q3 2015.

  • Geneva Advisors reported no remaining Celldex Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Geneva Advisors sold 749 Celldex Therapeutics shares in Q3 2015, an estimated $283K.
  • Geneva Advisors first reported a position in Celldex Therapeutics in Q1 2015 and held it in 2 quarters.
  • Geneva Advisors's Celldex Therapeutics position peaked at $283K in Q2 2015.
  • 162 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2015.

Based on Geneva Advisors's 13F filing for Q3 2015, filed 3 Nov 2015.